Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9H3R0

UPID:
KDM4C_HUMAN

ALTERNATIVE NAMES:
Gene amplified in squamous cell carcinoma 1 protein; JmjC domain-containing histone demethylation protein 3C; Jumonji domain-containing protein 2C; [histone H3]-trimethyl-L-lysine(9) demethylase 4C

ALTERNATIVE UPACC:
Q9H3R0; B4E1Y4; B7ZL46; F5H347; F5H7P0; O94877; Q2M3M0; Q5JUC9; Q5VYJ2; Q5VYJ3

BACKGROUND:
The protein Lysine-specific demethylase 4C, alternatively named JmjC domain-containing histone demethylation protein 3C, is central to the histone code through its specific action on 'Lys-9' and 'Lys-36' of histone H3. It does not interact with other lysine residues, showcasing its specificity and importance in epigenetic regulation. This enzyme's activity is crucial for the proper regulation of gene expression, impacting cellular function and identity.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Lysine-specific demethylase 4C unveils potential pathways for therapeutic development. Its crucial role in histone demethylation and gene expression regulation makes it a promising target for epigenetic therapy, paving the way for innovative treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.